Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
AI is poised to transform oncology with innovative tools enhancing diagnosis, treatment, and clinical trials, despite some wariness from clinicians and patients.
How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care Playbook
In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.
Banner Year for Bispecifics as Therapies Advance Into the Community Setting
As Myeloma Trials Tackle Frontline Treatment, Where Are the Black Patients?
Table Multiple Myeloma Trials November 2024
Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy
Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers
Health Care Practitioners Push for Legislative Solution to Prevent Chemotherapy Shortage “Groundhog Day”
From CAR T’s “Wait List Mortality” to “Tethering” Bispecific Antibodies, Oncologists Navigate Time-Sensitive Sequencing in Multiple Myeloma
Navigating Decision-Making When Treating Lymphoma With Bispecific Antibodies vs CAR T-Cell Therapy
